# Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Source: https://onco.cc/trials/nct00033332/  
OnCo record `nct00033332` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Dexamethasone, Pamidronate, Thalidomide and Zoledronic acid in Multiple myeloma, run by National Cancer Institute (NCI), completed.

## Summary

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma is a phase 3 interventional study registered as NCT00033332 by National Cancer Institute (NCI), started 2002-04 and reaching its primary completion in 2006-03. Interventions recorded: dexamethasone, pamidronate disodium, thalidomide, zoledronic acid. Conditions recorded: Multiple Myeloma and Plasma Cell Neoplasm.

Linked to the drug Pamidronate because the registry names it among its interventions and Multiple myeloma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00033332
- Phase: 3
- Setting: A Randomized Phase III Trial Of Thalidomide (NSC # 66847) Plus Dexamethasone Versus Dexamethasone In Newly Diagnosed Multiple Myeloma
- Sponsor: National Cancer Institute (NCI)

## Sources

- ClinicalTrials.gov NCT00033332: https://clinicaltrials.gov/study/NCT00033332

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Pamidronate](https://onco.cc/drugs/pamidronate/), [Thalidomide](https://onco.cc/drugs/thalidomide/), [Zoledronic acid](https://onco.cc/drugs/zoledronic-acid/)

---
JSON: https://onco.cc/api/v1/entities/nct00033332.json